<DOC>
	<DOC>NCT02004886</DOC>
	<brief_summary>This study will assess the safety, tolerability and glucose-lowering efficacy of MK-0893 in participants with type 2 diabetes mellitus. The primary hypothesis is that MK-0893 will reduce 24-hour weighted mean glucose (WMG) significantly more than placebo.</brief_summary>
	<brief_title>A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
	<criteria>Type 2 diabetes Not currently on antihyperglycemic agent (AHA) or AHA monotherapy (not to include treatment with insulin or thiazolidinediones [i.e., peroxisome proliferator activated receptorgamma, PPARγ agents]) male or a female of nonchildbearing potential. Women must be postmenopausal or premenopausal and documented surgically sterilized A body mass index (BMI) that is &gt; 20 and ≤ 40 kg/m2 History of type 1 diabetes or assessed by the investigator as possibly having type 1 diabetes History of ketoacidosis; clinically unstable or rapidly progressive diabetic retinopathy, nephropathy, neuropathy Treatment for diabetes within 3 months of study participation with combination antihyperglycemic therapy, insulin or thiazolidinediones (e.g., rosiglitazone or pioglitazone) oral corticosteroid medications within 2 weeks prior to study participation, or requires digoxin, warfarin, warfarinlike anticoagulants, theophylline, antidysrhythmic or antiseizure medications, immunosuppressants, or antineoplastic agents, or herbal remedies History of acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus (HIV) History of gastrointestinal problems or disorders or extensive bowel or gastric surgery History of significant or unstable cardiovascular disease History of neoplastic disease History of hepatic disease History of seizures, epilepsy or other neurologic disease History of myelodysplastic or preleukemic disorders or other severe hematological disorder</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Diabetes Mellitus, Type 2</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Molecular Mechanisms of Pharmacological Action</keyword>
	<keyword>Physiological Effects of Drugs</keyword>
	<keyword>Metformin</keyword>
</DOC>